We have reported that low-energy extracorporeal shock wave (SW) therapy improves cardiac function in a pig model of chronic myocardial ischemia by up-regulating vascular endothelial growth factor and enhancing angiogenesis. We have also conducted a series of clinical studies in patients with refractory angina pectoris without indication of PCI or CABG. Low-energy SWs were applied from the body surface to ischemic myocardium. In the first open study, the SW therapy significantly improved symptoms and myocardial perfusion. In the second double-blind and placebo-controlled study, symptoms and cardiac function were significantly improved by the SW therapy but not by placebo therapy. No adverse effects were noted. We also demonstrated that the SW therapy significantly improved symptoms, walking ability, and peripheral perfusion in patients with peripheral arterial disease and intermittent claudication. These results suggest that the low-energy SW therapy is promising, non-invasive and effective regenerative option for wide a range of cardiovascular disorders.
|Journal||Transactions of Japanese Society for Medical and Biological Engineering|
|Publication status||Published - 2014 Aug 17|
- Angina pectoris
- Peripheral arterial disease
- Shock wave therapy
ASJC Scopus subject areas
- Biomedical Engineering